Literature DB >> 9708940

The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens.

A A Renshaw1, J P Richie, K R Loughlin, M Jiroutek, A Chung, A V D'Amico.   

Abstract

BACKGROUND: Tumor volume in radical prostatectomies can be determined by several different techniques and appears to predict clinical progression. Greatest tumor dimension and area are easily obtained measures that are both correlated with tumor volume. The authors sought to determine whether greatest tumor dimension and/or area were predictors of prostate specific antigen (PSA) failure in men who underwent radical prostatectomy for adenocarcinoma of the prostate.
METHODS: Fifty-seven men with prostate carcinoma who underwent surgical resection were followed for a median of 27.2 months (range, 1-112 months); 24 (42%) of these men had PSA failure. Preoperative PSA, Gleason grade, pathologic stage, margin status, and greatest tumor dimension and area were determined, and both univariate and multivariate analyses of the outcomes of PSA failure were performed.
RESULTS: In the univariate analysis, larger values of greatest tumor dimension and area were strongly associated with increased incidence of PSA failure (P = 0.0001 and 0.0011, respectively). The forward stepwise multivariate analysis indicated that greatest tumor dimension had marginal statistical significance as a risk factor for PSA failure (P = 0.0577; risk ratio, 1.117). However, in this series, men with a greatest tumor dimension of less than 1 cm did not experience failure, whereas all patients with a greatest tumor dimension of more than 2 cm did.
CONCLUSIONS: Measuring greatest tumor dimension is a simple, inexpensive predictor of PSA failure in men who have undergone radical prostatectomy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708940

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Maximum tumor diameter adjusted to the risk profile predicts biochemical recurrence after radical prostatectomy.

Authors:  Georg Müller; Malte Rieken; Gernot Bonkat; Joel Roman Gsponer; Tatjana Vlajnic; Christian Wetterauer; Thomas C Gasser; Stephen F Wyler; Alexander Bachmann; Lukas Bubendorf
Journal:  Virchows Arch       Date:  2014-08-17       Impact factor: 4.064

2.  In Organ-confined Prostate Cancer, Tumor Quantitation Not Found to Aid in Prediction of Biochemical Recurrence.

Authors:  Yujiro Ito; Emily A Vertosick; Daniel D Sjoberg; Andrew J Vickers; Hikmat A Al-Ahmadie; Ying-Bei Chen; Anuradha Gopalan; Sahussapont J Sirintrapun; Satish K Tickoo; James A Eastham; Peter T Scardino; Victor E Reuter; Samson W Fine
Journal:  Am J Surg Pathol       Date:  2019-08       Impact factor: 6.394

3.  Evaluating the size criterion for PI-RADSv2 category 5 upgrade: is 15 mm the best threshold?

Authors:  Julie Y An; Stephanie A Harmon; Sherif Mehralivand; Marcin Czarniecki; Clayton P Smith; Julie A Peretti; Bradford J Wood; Peter A Pinto; Peter L Choyke; Joanna H Shih; Baris Turkbey
Journal:  Abdom Radiol (NY)       Date:  2018-12

4.  Significance of predicted tumor volume as a predictor of pathologic stage in patients undergoing radical prostatectomy.

Authors:  Ja Hyeon Ku; Kyung Chul Moon; Cheol Kwak; Hyeon Hoe Kim
Journal:  Korean J Urol       Date:  2011-01-24

5.  Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer.

Authors:  I M van Oort; J A Witjes; D E G Kok; L A L M Kiemeney; C A Hulsbergen-vandeKaa
Journal:  World J Urol       Date:  2008-02-12       Impact factor: 4.226

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.